Form 4: Abbott CEO Robert Ford Buys 18,800 Shares
Insider Transaction Report
Abbott Laboratories' Chairman and CEO, Robert B. Ford, acquired 18,800 common shares at a weighted average price of $107.1259.
Summary
- Robert B. Ford, Chairman and CEO of Abbott Laboratories (ABT), acquired 18,800 common shares.
- The transaction took place on January 23, 2026, and was executed under a Rule 10b5-1 plan.
- The shares were purchased at a weighted average price of $107.1259, with individual transaction prices ranging from $106.735 to $107.485.
- Following this acquisition, the Ford Family Trust indirectly holds 216,203 common shares.
- Robert B. Ford also directly beneficially owns 253,305 common shares.
Sentiment
Score: 7
Explanation: The acquisition of shares by the CEO is a positive indicator of management confidence. However, as a single transaction, it provides limited insight into broader company performance or strategic shifts.
Positives
- Chairman and CEO Robert B. Ford's acquisition of 18,800 common shares signals management's confidence in Abbott Laboratories' future prospects and valuation.
- The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-planned and systematic investment strategy.
Future Outlook
This Form 4 filing reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
Insider purchases by a company's Chairman and CEO are generally viewed as a positive signal by the market, indicating strong belief in the company's current valuation and future prospects within the competitive healthcare and medical products industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Robert B. Ford granted power of attorney to Elizabeth C. Cushman, Jessica H. Paik, and Aaron N. Rice to prepare, sign, and file SEC forms and documents, including those required under Rule 144 and Section 16(a). | June 13, 2025 | This procedural change streamlines the process for filing required SEC documents for the reporting person, ensuring timely compliance with federal securities laws. |
Stakeholder Impact
- Shareholders may interpret the CEO's share purchase as a positive sign of management's conviction in the company's value, potentially enhancing investor confidence.
Key Dates
| Date | Description |
|---|---|
| June 13, 2025 | Date Robert B. Ford signed the Power of Attorney document. |
| January 23, 2026 | Date of the common share acquisition transaction. |
| January 26, 2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Abbott Laboratories, ABT, Insider Trading, Form 4, Stock Purchase, CEO, Robert B. Ford, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.